About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

NEST (Nurturing Excellence Strengthening Talent), an initiative by Novartis led by the Development Hub in India aimed to ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

NEST (Nurturing Excellence Strengthening Talent), an initiative by Novartis led by the Development Hub in India aimed to ...

The "Seizures Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The Seizures treatment pipeline analysis provides an overview of recent advancements ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Health insurance companies are “very concerned” about their ability to force lower prices being restricted after a court ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...